On June 16th, our recently work “A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy” was published on Nature Nanotechnology (2025, doi: org/10.1038/s41565-025-01952-x). Our laboratory has focused on biomimetic nanovesicle-based drug delivery and immunotherapy. Here we propose a nanovaccine strategy, called NICER, based on a nanovesicle system integrating CSC-specific antigen display and epigenetic nano-regulator encapsulation with a dendritic-cell-targeting aptamer. Specifically, nanovesicles derived from aldehyde-dehydrogenase-overexpressing tumours could serve as integrated antigens carrying both CSC-specific antigen and tumour-associated antigens. Epigenetic nano-regulator targeting YTH N6-methyladenosine RNA binding protein 1 could restrict dendritic cell lysosomal protease activity to modulate...
Recently released in the 2024 Journal Citation Reports™ (JCR) by Clarivate, the Impact Factor of Theranostics has significantly increased to 13.3, marking progressive growth from the previous year's IF of 12.4. This achievement further underscores the journal's prominent position in the fields of translational medicine and precision medicine. According to the JCR 2024, The IF 13.3 of Theranostics not only sets a new historical high for the journal but also firmly places it among the top tier (top 1%) of global medical journals (Medicine category). The journal has consistently demonstrated growth over multiple consecutive years. This accomplishment reflects the high recognition by the global scientific community of the academic quality, innovative value, and international citation impact of the research published in Theranostics. As a flagship journal in t...